Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

* Conducting an initial small, controlled trial to assess therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients without AIDS * 20 HIV (+) patients with AIDS * Positive HIV testing by standard RT-PCR assay or equivalent testing * No symptoms of AIDS * No clinical signs indicative of Severe or Critical Illness Severity * HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix * By the percutaneous route with the multiple puncture device * Negative HIV testing by standard RT-PCR assay or equivalent testing after percutaneous use 3 weeks. * Positive IGRA blood test with GP160 antigen after percutaneous use 21 days. * Our trial duration will be up to 4 weeks.